Sarepta Therapeutics (SRPT) Tops Q3 EPS by 7c; Raises FY Revenue outlook

Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($0.78), $0.07 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $46 million versus the consensus estimate of $40.77 million.

GUIDANCE:

Sarepta Therapeutics sees FY2017 revenue of $150-155 million, versus the consensus of $139.45 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
• Activist investor presses Xerox to review financial services arm - Bloomberg
• GE Aerospace to acquire Consolidated Precision in $11.75b deal